Rheumatoid arthritis
References
Key articles
Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021 Jul;73(7):1108-23.Full text Abstract
National Institute for Health and Care Excellence. Rheumatoid arthritis in adults: management. Oct 2020 [internet publication].Full text
Smolen JS, Landewé RBM, Bergstra SA, eta al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18 Epub 2022 Nov 10.Full text Abstract
Reference articles
1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001 Sep 15;358(9285):903-11. Abstract
2. Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014 Jul;73(7):1316-22. Abstract
3. Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019 Nov;78(11):1463-71. Abstract
4. Almutairi KB, Nossent JC, Preen DB, et al. The prevalence of rheumatoid arthritis: a systematic review of population-based studies. J Rheumatol. 2021 May;48(5):669-76. Abstract
5. Pincus T, Sokka T. How can the risk of long-term consequences of rheumatoid arthritis be reduced? Best Pract Res Clin Rheumatol. 2001 Mar;15(1):139-70. Abstract
6. Kavanaugh AF. Rheumatoid arthritis in the elderly: is it a different disease? Am J Med. 1997 Dec 29;103(6A):40-8S. Abstract
7. Yazici Y, Paget SA. Elderly-onset rheumatoid arthritis. Rheum Dis Clin North Am. 2000 Aug;26(3):517-26. Abstract
8. Cojocaru M, Cojocaru IM, Silosi I, et al. Extra-articular manifestations in rheumatoid arthritis. Maedica (Bucur). 2010 Dec;5(4):286-91.Full text Abstract
9. Hunter TM, Boytsov NN, Zhang X, et al. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. Rheumatol Int. 2017 Sep;37(9):1551-7. Abstract
10. Ye D, Mao Y, Xu Y, et al. Lifestyle factors associated with incidence of rheumatoid arthritis in US adults: analysis of National Health and Nutrition Examination Survey database and meta-analysis. BMJ Open. 2021 Jan 26;11(1):e038137.Full text Abstract
11. Sugiyama D, Nishimura K, Tamaki K, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2010 Jan;69(1):70-81. Abstract
12. Källberg H, Ding B, Padyukov L, et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis. 2011 Mar;70(3):508-11.Full text Abstract
13. Hutchinson D, Shepstone L, Moots R, et al. Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA. Ann Rheum Dis. 2001 Mar;60(3):223-7.Full text Abstract
14. Abhishek A, Doherty M, Kuo CF, et al. Rheumatoid arthritis is getting less frequent - results of a nationwide population-based cohort study. Rheumatology (Oxford). 2017 May 1;56(5):736-44.Full text Abstract
15. Uhlig T, Kvien TK. Is rheumatoid arthritis disappearing? Ann Rheum Dis. 2005 Jan;64(1):7-10.Full text Abstract
16. Salari N, Kazeminia M, Shohaimi S, et al. Socioeconomic inequality in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2021 Nov;40(11):4511-25.Full text Abstract
17. Frisell T, Saevarsdottir S, Askling J. Family history of rheumatoid arthritis: an old concept with new developments. Nat Rev Rheumatol. 2016 Jun;12(6):335-43. Abstract
18. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987 Nov;30(11):1205-13. Abstract
19. van der Helm-van Mil AH, Huizinga TW, de Vries RR, et al. Emerging patterns of risk factor make-up enable subclassification of rheumatoid arthritis. Arthritis Rheum. 2007 Jun;56(6):1728-35. Abstract
20. Mustelin T, Bottini N, Stanford SM. The contribution of PTPN22 to rheumatic disease. Arthritis Rheumatol. 2019 Mar 2;71(4):486-95. Abstract
21. Gravallese EM, Firestein GS. Rheumatoid arthritis - common origins, divergent mechanisms. N Engl J Med. 2023 Feb 9;388(6):529-42.Full text Abstract
22. Chen P, Li Y, Li L, et al. Association between the interleukin (IL)-17A rs2275913 polymorphism and rheumatoid arthritis susceptibility: a meta-analysis and trial sequential analysis. J Int Med Res. 2021 Oct;49(10):3000605211053233.Full text Abstract
23. Pacheco-Soto BT, Porchia LM, Lara-Vazquez WC, et al. The association between interleukin-6 promoter polymorphisms and rheumatoid arthritis by ethnicity: a meta-analysis of 33 studies. Reumatol Clin (Engl Ed). 2021 Oct;17(8):447-55.Full text Abstract
24. Agonia I, Couras J, Cunha A, et al. IL-17, IL-21 and IL-22 polymorphisms in rheumatoid arthritis: a systematic review and meta-analysis. Cytokine. 2020 Jan;125:154813.Full text Abstract
25. Shao M, Xie H, Yang H, et al. Association of interleukin-6 promoter polymorphism with rheumatoid arthritis: a meta-analysis with trial sequential analysis. Clin Rheumatol. 2022 Feb;41(2):411-9.Full text Abstract
26. Gibofsky A. Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsis. Am J Manag Care. 2014 May;20(7 suppl):S128-35.Full text Abstract
27. Ishikawa Y, Terao C. The impact of cigarette smoking on risk of rheumatoid arthritis: a narrative review. Cells. 2020 Feb 19;9(2).Full text Abstract
28. Karlson EW, Chang SC, Cui J, et al. Gene-environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis. Ann Rheum Dis. 2010 Jan;69(1):54-60.Full text Abstract
29. Too CL, Yahya A, Murad S, et al. Smoking interacts with HLA-DRB1 shared epitope in the development of anti-citrullinated protein antibody-positive rheumatoid arthritis: results from the Malaysian Epidemiological Investigation of Rheumatoid Arthritis (MyEIRA). Arthritis Res Ther. 2012 Apr 26;14(2):R89.Full text Abstract
30. Li X, Zhu J, Zhao W, et al. The causal effect of obesity on the risk of 15 autoimmune diseases: a mendelian randomization study. Obes Facts. 2023;16(6):598-605.Full text Abstract
31. Khanna D, Khanna S, Khanna P, et al. Obesity: a chronic low-grade inflammation and its markers. Cureus. 2022 Feb;14(2):e22711.Full text Abstract
32. Deane KD, Demoruelle MK, Kelmenson LB, et al. Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017 Sep 18;31(1):3-18.Full text Abstract
33. Batool A, Vaithilingam RD, Mohamad Hassan NH, et al. Evaluating the potential of matrix metalloproteinase as a diagnostic biomarker in rheumatoid arthritis and periodontitis: a systematic review and meta-analysis. Medicine (Baltimore). 2023 Oct 13;102(41):e35340.Full text Abstract
34. Jaśkiewicz Ł, Chmielewski G, Kuna J, et al. The role of sclerostin in rheumatic diseases: a review. J Clin Med. 2023 Sep 28;12(19).Full text Abstract
35. Mao YM, Liao T, Ye QL, et al. Increased circulating sclerostin levels in rheumatoid arthritis patients: an updated meta-analysis. Z Rheumatol. 2023 Jan;82(suppl 1):51-8.Full text Abstract
36. Bottazzi B, Inforzato A, Messa M, et al. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol. 2016 Jun;64(6):1416-27.Full text Abstract
37. Zlibut A, Bocsan IC, Agoston-Coldea L. Pentraxin-3 and endothelial dysfunction. Adv Clin Chem. 2019;91:163-79.Full text Abstract
38. Guan SY, Chen Y, Shao M, et al. Increased circulating pentraxin 3 levels in patients with rheumatoid arthritis: a meta-analysis. Curr Pharm Des. 2022;28(27):2260-9.Full text Abstract
39. Frisell T, Holmqvist M, Källberg H, et al. Familial risks and heritability of rheumatoid arthritis: role of rheumatoid factor/anti-citrullinated protein antibody status, number and type of affected relatives, sex, and age. Arthritis Rheum. 2013 Nov;65(11):2773-82.Full text Abstract
40. Giri PS, Dwivedi M. Meta-analysis for association of interleukin 4 VNTR polymorphism with rheumatoid arthritis risk and severity. Biochem Genet. 2023 Jun;61(3):823-46.Full text Abstract
41. Bagheri-Hosseinabadi Z, Imani D, Yousefi H, et al. Vitamin D receptor (VDR) gene polymorphism and risk of rheumatoid arthritis (RA): systematic review and meta-analysis. Clin Rheumatol. 2020 Dec;39(12):3555-69.Full text Abstract
42. Zhu L, Chen P, Sun X, et al. Associations between polymorphisms in the IL-1 gene and the risk of rheumatoid arthritis and systemic lupus erythematosus: evidence from a meta-analysis. Int Arch Allergy Immunol. 2021;182(3):234-42.Full text Abstract
43. Zhang X, Zhang X, Yang Y, et al. Association between passive smoking and the risk of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2023 Mar;42(3):663-72.Full text Abstract
44. Rakieh C, Nam JL, Hunt L, et al. Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study. Ann Rheum Dis. 2015 Sep;74(9):1659-66. Abstract
45. Nam JL, Hunt L, Hensor EM, et al. Enriching case selection for imminent RA: the use of anti-CCP antibodies in individuals with new non-specific musculoskeletal symptoms - a cohort study. Ann Rheum Dis. 2016 Aug;75(8):1452-6. Abstract
46. Cope AP, Jasenecova M, Vasconcelos JC, et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet. 2024 Mar 2;403(10429):838-49.Full text Abstract
47. Rech J, Tascilar K, Hagen M, et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024 Mar 2;403(10429):850-9.Full text Abstract
48. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569-81.Full text Abstract
49. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021 Jul;73(7):1108-23.Full text Abstract
50. National Rheumatoid Arthritis Society. What is RA? May 2015 [internet publication].Full text
51. Aho K, Palusuo T, Kurki P. Marker antibodies of rheumatoid arthritis: diagnostic and pathogenetic implications. Semin Arthritis Rheum. 1994 Jun;23(6):379-87. Abstract
52. Goldbach-Mansky R, Lee J, McCoy A, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. 2000;2(3):236-43. Abstract
53. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 2004 Mar;50(3):709-15. Abstract
54. Wolfe F, Michaud K. The clinical and research significance of the erythrocyte sedimentation rate. J Rheumatol. 1994 Jul;21(7):1227-37. Abstract
55. Mohan C, Assassi S. Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity? BMJ. 2015 Nov 26;351:h5079. Abstract
56. Colebatch AN, Edwards CJ, Ostergaard M, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013;72:804-814. Abstract
57. American College of Radiology. ACR appropriateness criteria®: chronic extremity joint pain - suspected inflammatory arthritis. 2022 [internet publication].Full text Abstract
58. Takase-Minegishi K, Horita N, Kobayashi K, et al. Diagnostic test accuracy of ultrasound for synovitis in rheumatoid arthritis: systematic review and meta-analysis. Rheumatology (Oxford). 2018 Jan 1;57(1):49-58.Full text Abstract
59. Lage-Hansen PR, Lindegaard H, Chrysidis S, et al. The role of ultrasound in diagnosing rheumatoid arthritis, what do we know? An updated review. Rheumatol Int. 2017 Feb;37(2):179-87. Abstract
60. Freeston JE, Wakefield RJ, Conaghan PG, et al. A diagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment tools. Ann Rheum Dis. 2010 Feb;69(2):417-9. [Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.] Abstract
61. Simpson E, Hock E, Stevenson M, et al. What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis. Health Technol Assess. 2018 Apr;22(20):1-258.Full text Abstract
62. National Institute for Health and Care Excellence. Rheumatoid arthritis in adults: management. Oct 2020 [internet publication].Full text
63. van der Heijde DM, van 't Hof M, van Riel PL, et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993 Mar;20(3):579-81. Abstract
64. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S100-8. Abstract
65. Pincus T, Yazici Y, Bergman M, et al. A proposed approach to recognise "near-remission" quantitatively without formal joint counts or laboratory tests: a patient self-report questionnaire routine assessment of patient index data (RAPID) score as a guide to a "continuous quality improvement". Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-60-5. Abstract
66. Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012 May;64(5):640-7.Full text Abstract
67. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007 Mar 20;146(6):406-15. Abstract
68. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004 Jul 17-23;364(9430):263-9. Abstract
69. Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis. 2011 Jun;70(6):1039-46. Abstract
70. Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011 Mar;63(3):633-9.Full text Abstract
71. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315-24.Full text Abstract
72. Allen A, Carville S, McKenna F, et al. Diagnosis and management of rheumatoid arthritis in adults: summary of updated NICE guidance. BMJ. 2018 Aug 3;362:k3015. Abstract
73. Efthimiou P, Kontzias A, Hur P, et al. Adult-onset Still's disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Semin Arthritis Rheum. 2021 Aug;51(4):858-74.Full text Abstract
74. Franchini S, Dagna L, Salvo F, et al. Adult onset Still's disease: clinical presentation in a large cohort of Italian patients. Clin Exp Rheumatol. 2010 Jan-Feb;28(1):41-8.Full text Abstract
75. Hu QY, Zeng T, Sun CY, et al. Clinical features and current treatments of adult-onset Still's disease: a multicentre survey of 517 patients in China. Clin Exp Rheumatol. 2019 Nov-Dec;37 Suppl 121(6):52-7.Full text Abstract
76. Liu Z, Lv X, Tang G. Clinical features and prognosis of adult-onset Still's disease: 75 cases from China. Int J Clin Exp Med. 2015;8(9):16634-9.Full text Abstract
77. Riera E, Olivé A, Narváez J, et al. Adult onset Still's disease: review of 41 cases. Clin Exp Rheumatol. 2011 Mar-Apr;29(2):331-6.Full text Abstract
78. Zeng T, Zou YQ, Wu MF, et al. Clinical features and prognosis of adult-onset still's disease: 61 cases from China. J Rheumatol. 2009 May;36(5):1026-31.Full text Abstract
79. Chen DY, Lan JL, Hsieh TY, et al. Clinical manifestations, disease course, and complications of adult-onset Still's disease in Taiwan. J Formos Med Assoc. 2004 Nov;103(11):844-52.Full text Abstract
80. Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still's disease. J Autoimmun. 2018 Sep;93:24-36.Full text Abstract
81. Mitrovic S, Fautrel B. New markers for adult-onset still's disease. Joint Bone Spine. 2018 May;85(3):285-93.Full text Abstract
82. Vordenbäumen S, Feist E, Rech J, et al. Diagnosis and treatment of adult-onset Still's disease: a concise summary of the German society of rheumatology S2 guideline. Z Rheumatol. 2023 Feb;82(suppl 2):81-92.Full text Abstract
83. Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016 Jun 30;374(26):2575-84.Full text Abstract
84. Tedeschi SK, Becce F, Pascart T, et al. Imaging features of calcium pyrophosphate deposition disease: consensus definitions from an iInternational Multidisciplinary Working Group. Arthritis Care Res (Hoboken). 2023 Apr;75(4):825-34.Full text Abstract
85. Nagy G, Roodenrijs NMT, Welsing PM, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021 Jan;80(1):31-5.Full text Abstract
86. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011 Mar;63(3):573-86.Full text Abstract
87. Studenic P, Aletaha D, de Wit M, et al. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Arthritis Rheumatol. 2023 Jan;75(1):15-22.Full text Abstract
88. Smolen JS, Landewé RBM, Bergstra SA, eta al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18 Epub 2022 Nov 10.Full text Abstract
89. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously - predictive markers, socioeconomic status and comorbidity. J Rheumatol. 1986 Oct;13(5):841-5. Abstract
90. Curtis JR, Emery P, Karis E, et al. Etanercept or methotrexate withdrawal in rheumatoid arthritis patients in sustained remission. Arthritis Rheumatol. 2021 May;73(5):759-68.Full text Abstract
91. Lillegraven S, Paulshus Sundlisæter N, Aga AB, et al. Effect of half-dose vs stable-dose conventional synthetic disease-modifying antirheumatic drugs on disease flares in patients with rheumatoid arthritis in remission: the ARCTIC REWIND randomized clinical trial. JAMA. 2021 May 4;325(17):1755-64.Full text Abstract
92. Meng CF, Rajesh DA, Jannat-Khah DP, et al. Can patients with controlled rheumatoid arthritis taper methotrexate from targeted therapy and sustain remission? a systematic review and metaanalysis. J Rheumatol. 2023 Jan;50(1):36-47.Full text Abstract
93. Wang X, Tang Z, Huang T, et al. Withdrawal of MTX in rheumatoid arthritis patients on bDMARD/tsDMARD plus methotrexate at target: a systematic review and meta-analysis. Rheumatology (Oxford). 2023 Apr 3;62(4):1410-16.Full text Abstract
94. Vasconcelos LB, Silva MT, Galvao TF. Reduction of biologics in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Int. 2020 Dec;40(12):1949-59.Full text Abstract
95. D Vinson, LM Benhamou, Y Degboé, et al. Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis. Arthritis Research & Therapy. 2020 Apr 29;22(1):97.Full text
96. Lillegraven S, Paulshus Sundlisæter N, Aga AB, et al. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial. Ann Rheum Dis. 2023 Nov;82(11):1394-403.Full text Abstract
97. Palmowski A, Pankow A, Terziyska K, et al. Continuing versus tapering low-dose glucocorticoids in patients with rheumatoid arthritis and systemic lupus erythematosus in states of low disease activity or remission: a systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2024 Feb;64:152349.Full text Abstract
98. Xu J, Xiao L, Zhu J, et al. Methotrexate use reduces mortality risk in rheumatoid arthritis: a systematic review and meta-analysis of cohort studies. Semin Arthritis Rheum. 2022 Aug;55:152031.Full text Abstract
99. ter Wee MM, den Uyl D, Boers M, et al. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. Ann Rheum Dis. 2015 Jun;74(6):1233-40. Abstract
100. Ota R, Hata T, Hirata A, et al. Risk of infection from glucocorticoid and methotrexate interaction in patients with rheumatoid arthritis using biologics: a retrospective cohort study. Br J Clin Pharmacol. 2023 Jul;89(7):2168-78.Full text Abstract
101. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014 Aug;73(8):1549-51.Full text Abstract
102. van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009 Aug 8;374(9688):459-66. Abstract
103. Bijlsma JW, Welsing PM, Woodworth TG, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet. 2016 Jul 23;388(10042):343-55. Abstract
104. Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis. 2015 Jun;74(6):1037-44.Full text Abstract
105. Donahue KE, Gartlehner G, Schulman ER, et al. Drug therapy for early rheumatoid arthritis: a systematic review update. Jul 2018 [internet publication].Full text Abstract
106. Serhal L, Edwards CJ. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2018 Nov 19;15(1):13-25. Abstract
107. Tarp S, Jørgensen TS, Furst DE, et al. Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: a systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2019 Jun;48(6):958-66.Full text Abstract
108. Lend K, Koopman FA, Lampa J, et al. Methotrexate safety and efficacy in combination therapies in patients with early rheumatoid arthritis: a post hoc analysis of a randomized controlled trial. Arthritis Rheumatol. 2024 Mar;76(3):363-76.Full text Abstract
109. Nayebirad S, Javinani A, Javadi M, et al. The effect of smoking on response to methotrexate in rheumatoid arthritis patients: a systematic review and meta-analysis. Mod Rheumatol. 2023 Dec 22;34(1):68-78.Full text Abstract
110. Lee YH, Bae SC. Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis: meta-analysis of randomized controlled trials. Z Rheumatol. 2017 Aug;76(6):528-34. Abstract
111. Schmitz S, Adams R, Walsh CD, et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum Dis. 2012 Feb;71(2):225-30. Abstract
112. Murray E, Ellis A, Butylkova Y, et al. Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritis. J Comp Eff Res. 2018 Oct;7(10):959-74.Full text Abstract
113. National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed. Jul 2021 [internet publication].Full text
114. Ji X, Hu L, Wang Y, et al. Risk of tuberculosis in patients with rheumatoid arthritis treated with biological and targeted drugs: meta-analysis of randomized clinical trials. Chin Med J (Engl). 2022 Jan 12;135(4):409-15.Full text Abstract
115. Michaud TL, Rho YH, Shamliyan T, et al. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med. 2014 Dec;127(12):1208-32. Abstract
116. Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017 Jun;76(6):1101-36.Full text Abstract
117. Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2011 Jun;63(6):1479-85.Full text Abstract
118. Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2015 Jun;74(6):1087-93.Full text Abstract
119. Bonovas S, Minozzi S, Lytras T, et al. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016 Dec;15(sup1):35-54. Abstract
120. Wetzman A, Lukas C, Gaujoux-Viala C, et al. Risk of cancer after initiation of targeted therapies in patients with rheumatoid arthritis and a prior cancer: systematic review with meta-analysis. Arthritis Care Res (Hoboken). 2023 Feb;75(2):260-71.Full text Abstract
121. Xie W, Xiao S, Huang Y, et al. A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy. Rheumatology (Oxford). 2020 May 1;59(5):930-9.Full text Abstract
122. Wang JL, Yin WJ, Zhou LY, et al. Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis. Clin Rheumatol. 2020 Mar;39(3):769-78.Full text Abstract
123. Verhoef LM, van den Bemt BJ, van der Maas A, et al. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev. 2019 May 24;(5):CD010455.Full text Abstract
124. Henaux S, Ruyssen-Witrand A, Cantagrel A, et al. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Ann Rheum Dis. 2018 Apr;77(4):515-22. Abstract
125. Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015 Jun;67(6):1424-37.Full text Abstract
126. Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014 Sep;73(9):1626-34.Full text Abstract
127. Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016 Jun;75(6):1081-91.Full text Abstract
128. Sung YK, Lee YH. Comparison of the efficacy and safety of tocilizumab, sarilumab, and sirukumab in comparison with adalimumab as monotherapy in patients with active rheumatoid arthritis: a bayesian network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2021 Sep;59(9):618-26.Full text Abstract
129. Sung YK, Lee YH. Comparative efficacy and safety of biologic agents in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: a bayesian network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2022 Jan;60(1):13-23.Full text Abstract
130. Choy E, Freemantle N, Proudfoot C, et al. Indirect treatment comparison of the efficacy and safety of sarilumab monotherapy in rheumatoid arthritis patients with inadequate response to conventional disease-modifying antirheumatic drugs. Adv Ther. 2019 Apr;36(4):817-27.Full text Abstract
131. Sanmarti R, Veale DJ, Martin-Mola E, et al. Reducing or maintaining the dose of subcutaneous tocilizumab in patients with rheumatoid arthritis in clinical remission: a randomized, open-label trial. Arthritis Rheumatol. 2019 Oct;71(10):1616-25. Abstract
132. Bilal J, Berlinberg A, Riaz IB, et al. Risk of infections and cancer in patients with rheumatologic diseases receiving interleukin inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2019 Oct 2;2(10):e1913102.Full text Abstract
133. Lambert N, Hansen I, El Moussaoui M, et al. Lung and liver sarcoidosis-like reaction induced by tocilizumab. Br J Clin Pharmacol. 2021 Apr 26 [Epub ahead of print]. Abstract
134. Ko PH, Kuo MH, Kao IT, et al. The risk of hepatitis B virus reactivation in rheumatoid arthritis patients receiving tocilizumab: a systematic review and meta-analysis. Viruses. 2024 Jan 3;16(1).Full text Abstract
135. Katelani S, Fragoulis GE, Bakasis AD, et al. HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: a systematic review and meta-analysis. Rheumatology (Oxford). 2023 Oct 23;62(si3):SI252-9.Full text Abstract
136. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28-31 October 2019. Oct 2019 [internet publication].Full text
137. Medicines and Healthcare products Regulatory Agency. Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation. Jul 2019 [internet publication].Full text
138. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009 Dec;68(12):1870-7. Abstract
139. Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013 Jan;65(1):28-38.Full text Abstract
140. Mohamed Ahamada M, Wu X. Analysis of efficacy and safety of abatacept for rheumatoid arthritis: systematic review and meta-analysis. Clin Exp Rheumatol. 2023 Sep;41(9):1882-900.Full text Abstract
141. Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015 Jan;74(1):19-26.Full text Abstract
142. Hetland ML, Haavardsholm EA, Rudin A, et al. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ. 2020 Dec 2;371:m4328.Full text Abstract
143. Westhovens R, Robles M, Ximenes AC, et al. Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis. Ann Rheum Dis. 2015 Mar;74(3):564-8.Full text Abstract
144. Emery P, Burmester GR, Bykerk VP, et al. Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study. RMD Open. 2019;5(1):e000840.Full text Abstract
145. Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. Sep 2021 [internet publication].Full text
146. ClinicalTrials.gov. Safety study of tofacitinib versus tumor necrosis factor (TNF) inhibitor in subjects with rheumatoid arthritis (A3921133). NCT02092467. Aug 2021 [internet publication].Full text
147. European Medicines Agency. Janus kinase inhibitors (JAKi). Jan 2023 [internet publication].Full text
148. Salinas CA, Louder A, Polinski J, et al. Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases. Rheumatol Ther. 2023 Feb;10(1):201-23.Full text Abstract
149. National Institute for Health and Care Excellence. Filgotinib for treating moderate to severe rheumatoid arthritis. Feb 2021 [internet publication].Full text
150. National Institute for Health and Care Excellence. Upadacitinib for treating severe rheumatoid arthritis. Dec 2020 [internet publication].Full text
151. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002 Jan 1;136(1):1-12. Abstract
152. Pincus T, Huizinga TW, Yazici Y. N-of-1 trial of low-dose methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound, as first option in suspected rheumatoid arthritis? J Rheumatol. 2007 Feb;34(2):250-2. Abstract
153. Pincus T, Sokka T, Stein CM. Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful? Ann Intern Med. 2002 Jan 1;136(1):76-8. Abstract
154. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum. 2006 May;54(5):1401-9.Full text Abstract
155. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012 Mar 6;156(5):329-39.Full text Abstract
156. Safy M, Jacobs J, IJff ND, et al; Society for Rheumatology Research Utrecht (SRU). Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial. Ann Rheum Dis. 2017 Aug;76(8):1432-5. Abstract
157. Verschueren P, De Cock D, Corluy L, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015 Jan;74(1):27-34. Abstract
158. Adami G, Fassio A, Rossini M, et al. Bone loss in inflammatory rheumatic musculoskeletal disease patients treated with low-dose glucocorticoids and prevention by anti-osteoporosis medications. Arthritis Rheumatol. 2023 Oct;75(10):1762-9.Full text Abstract
159. Palmowski A, Nielsen SM, Boyadzhieva Z, et al. The effect of low-dose glucocorticoids over two years on weight and blood pressure in rheumatoid arthritis: individual patient data from five randomized trials. Ann Intern Med. 2023 Sep;176(9):1181-9.Full text Abstract
160. Burmester GR, Buttgereit F, Bernasconi C, et al. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. Lancet. 2020 Jul 25;396(10246):267-76. Abstract
161. Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis. 2013 Feb;72(2):204-10.Full text Abstract
162. Blavnsfeldt AG, de Thurah A, Thomsen MD, et al. The effect of glucocorticoids on bone mineral density in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized, controlled trials. Bone. 2018 Sep;114:172-80. Abstract
163. David P, Di Matteo A, Hen O, et al. Poly-refractory rheumatoid arthritis: an uncommon subset of difficult to treat disease with distinct inflammatory and noninflammatory phenotypes. Arthritis Rheumatol. 2024 Apr;76(4):510-21.Full text Abstract
164. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006 Jan;54(1):26-37. Abstract
165. Smolen JS, Van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006 Mar;54(3):702-10. Abstract
166. Klareskog L, van der Heijde D, de Jager JP, et al; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004 Feb 28;363(9410):675-81. Abstract
167. Janke K, Biester K, Krause D, et al. Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data. BMJ. 2020 Jul 7;370:m2288.Full text Abstract
168. Carmona L, Ortiz A, Abad MA. How good is to switch between biologics? A systematic review of the literature. Acta Reumatol Port. 2007 Apr-Jun;32(2):113-28. Abstract
169. Wells AF, Curtis JR, Betts KA, et al. Systematic literature review and meta-analysis of tumor necrosis factor-alpha experienced rheumatoid arthritis. Clin Ther. 2017 Jul 20;39(8):1680-94.e2. Abstract
170. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013 Jan;72(1):43-50.Full text Abstract
171. Fleischmann R, Kremer J, Cush J, et al; ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug 9;367(6):495-507.Full text Abstract
172. Gottenberg JE, Morel J, Perrodeau E, et al; French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ. 2019 Jan 24;364:l67.Full text Abstract
173. Källmark H, Einarsson JT, Nilsson JÅ, et al. Sustained remission in patients with rheumatoid arthritis receiving triple therapy compared to biologic therapy: a Swedish Nationwide Register study. Arthritis Rheumatol. 2021 Jul;73(7):1135-44.Full text Abstract
174. Mazouyès A, Clay M, Bernard AC, et al. Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: meta-analysis of randomized controlled trials. Joint Bone Spine. 2016 Dec 15;84(5):563-70. Abstract
175. Ostensen M, Villiger PM. The remission of rheumatoid arthritis during pregnancy. Semin Immunopathol. 2007 Jun;29(2):185-91. Abstract
176. Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2017 Oct 13;77(2):228-33.Full text Abstract
177. Humby F, Durez P, Buch MH, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021 Jan 23;397(10271):305-17.Full text Abstract
178. Smolen JS, Feist E, Fatenejad S, et al. Olokizumab versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2022 Aug 25;387(8):715-26.Full text Abstract
179. Abuelazm M, Ghanem A, Mahmoud A, et al. The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis. Clin Rheumatol. 2023 Jun;42(6):1503-20.Full text Abstract
180. Mahmoud AM. Olokizumab's effectiveness and safety in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. J Clin Densitom. 2023 Jan-Mar;26(1):61-82.Full text Abstract
181. Lee YH, Song GG. Comparative efficacy and safety of peficitinib 25, 50, 100, and 150 mg in patients with active rheumatoid arthritis: a bayesian network meta-analysis of randomized controlled trials. Clin Drug Investig. 2020 Jan;40(1):65-72.Full text Abstract
182. Lee YH, Song GG. Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: a bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis. 2020 Jul;23(7):868-75.Full text Abstract
183. Yang Y, Li J, Liu J, et al. Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study. Lancet Reg Health West Pac. 2024 Jan;42:100925.Full text Abstract
184. Wolfe F, Rasker JJ, Boers M, et al. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum. 2007 Aug 15;57(6):935-42. Abstract
185. Pincus T, Chung C, Segurado OG, et al. An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol. 2006 Nov;33(11):2146-52. Abstract
186. Pincus T, Sokka T. Complexities in the quantitative assessment of patients with rheumatic diseases in clinical trials and clinical care. Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S1-9. Abstract
187. Aletaha D, Smolen JS. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol. 2007 Aug;21(4):663-75. Abstract
188. Stevens JC, Beard CM, O'Fallon WM, et al. Conditions associated with carpal tunnel syndrome. Mayo Clin Proc. 1992 Jun;67(6):541-8. Abstract
189. Geoghegan JM, Clark DI, Bainbridge LC, et al. Risk factors in carpal tunnel syndrome. J Hand Surg Br. 2004 Aug;29(4):315-20. Abstract
190. ter Wee MM, Lems WF, Usan H, et al. The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review. Ann Rheum Dis. 2012 Feb;71(2):161-71. Abstract
191. Hansen PR, Feineis M, Abdulla J. Rheumatoid arthritis patients have higher prevalence and burden of asymptomatic coronary artery disease assessed by coronary computed tomography: a systematic literature review and meta-analysis. Eur J Intern Med. 2019 Apr;62:72-9. Abstract
192. Spagnolo P, Lee JS, Sverzellati N, et al. The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol. 2018 Sep 4;70(10):1544-54. Abstract
193. Yazici Y, Erkan D, Paget SA. Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events. Arthritis Rheum. 2003 Oct;48(10):2769-72. Abstract
194. Yazici Y, Erkan D, Paget SA. Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: is it time to update the guidelines? J Rheumatol. 2002 Aug;29(8):1586-9. Abstract
Use of this content is subject to our disclaimer